Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Operations: 2020-2024

Historic Cash from Operations for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to -$10.4 million.

  • Therapeutics' Cash from Operations rose 62.38% to -$10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$83.3 million, marking a year-over-year increase of 14.17%. This contributed to the annual value of -$83.3 million for FY2024, which is 14.17% up from last year.
  • Therapeutics' Cash from Operations amounted to -$10.4 million in Q4 2024, which was up 40.76% from -$17.6 million recorded in Q3 2024.
  • Over the past 5 years, Therapeutics' Cash from Operations peaked at -$6.4 million during Q2 2020, and registered a low of -$28.8 million during Q2 2023.
  • Over the past 3 years, Therapeutics' median Cash from Operations value was -$20.2 million (recorded in 2023), while the average stood at -$20.9 million.
  • As far as peak fluctuations go, Therapeutics' Cash from Operations tumbled by 116.52% in 2021, and later soared by 62.38% in 2024.
  • Quarterly analysis of 5 years shows Therapeutics' Cash from Operations stood at -$15.4 million in 2020, then plummeted by 34.59% to -$20.7 million in 2021, then declined by 10.48% to -$22.8 million in 2022, then decreased by 21.47% to -$27.8 million in 2023, then spiked by 62.38% to -$10.4 million in 2024.
  • Its Cash from Operations was -$10.4 million in Q4 2024, compared to -$17.6 million in Q3 2024 and -$28.2 million in Q2 2024.